Who is sponsoring NCT02297529?

NCT02297529 is sponsored by Amgen.

What drugs are being tested in NCT02297529?

Interventions in NCT02297529: Talimogene Laherparepvec.

What condition does NCT02297529 study?

NCT02297529 studies Unresected Stage IIIB to IVM1c Melanoma.

Is NCT02297529 still recruiting?

NCT02297529 is currently no longer available. Last updated 31 October 2019.

Last reviewed 2019-10-31 · How we verify

NCT02297529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

NO LONGER AVAILABLE Last updated 31 October 2019

What this trial tests

trial testing Talimogene Laherparepvec in Unresected Stage IIIB to IVM1c Melanoma. No longer available.

Quick facts

Lead sponsor	Amgen
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	3 locations across Switzerland

Drugs / interventions tested

Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) — full drug profile →

Conditions studied

Unresected Stage IIIB to IVM1c Melanoma — all drugs for Unresected Stage IIIB to IVM1c Melanoma →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 95, any sex, with Unresected Stage IIIB to IVM1c Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a phase 3b, multicenter, open-label, single-arm study designed to provide expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma. The study will also evaluate the safety and tolerability of Talimogene Laherparepvec.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch-Oncolytic viruses and cancer therapy.
Pol J, Buqué A, Aranda F, Bloy N, et al · · 2016 · cited 87× · PMID 27057469 · DOI 10.1080/2162402x.2015.1117740
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer.
Aldrak N, Alsaab S, Algethami A, Bhere D, et al · · 2021 · cited 61× · PMID 34207386 · DOI 10.3390/cells10061541
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O, Hoffner B, Gasal E, Hong J, et al · · 2017 · cited 59× · PMID 28712033 · DOI 10.1007/s00262-017-2025-8
From Benchtop to Bedside: A Review of Oncolytic Virotherapy.
Choi AH, O'Leary MP, Fong Y, Chen NG. · · 2016 · cited 46× · PMID 28536385 · DOI 10.3390/biomedicines4030018
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.
Meyers DE, Wang AA, Thirukkumaran CM, Morris DG. · · 2017 · cited 23× · PMID 28634571 · DOI 10.3389/fonc.2017.00114
Emerging delivery strategy for oncolytic virotherapy.
Zhu J, Ma J, Huang M, Deng H, et al · · 2024 · cited 15× · PMID 38845744 · DOI 10.1016/j.omton.2024.200809
Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers.
Ziogas DC, Martinos A, Petsiou DP, Anastasopoulou A, et al · · 2022 · cited 9× · PMID 35740539 · DOI 10.3390/cancers14122873

Verify or expand the search:

Other trials of Talimogene Laherparepvec

Trials testing the same drug.

NCT06660810 — Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · Phase 2 · active not recruiting
NCT04599062 — TVEC and Preop Radiation for Sarcoma (8 ml Dose) · Phase 1, PHASE2 · active not recruiting
NCT03554044 — T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer · Phase 1 · completed
NCT04163952 — Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of · Phase 1 · terminated
NCT02923778 — Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be · Phase 2 · active not recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02297529 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 31 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02297529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing